Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Compound 7p shows strong potential as an anticancer agent.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Cepharanthine shows promise as a potential lung cancer treatment by effectively killing cancer cells.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Ritlecitinib is cost-effective for severe alopecia areata in Japan.

Trametinib can cause skin issues, but they can often be managed without stopping the drug.

Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.

Ruxolitinib cream may help treat severe hair loss in children.

Sorafenib can cause rare skin reactions, but treatment can continue with additional care.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Tofacitinib helped a woman regrow hair with no major side effects.

Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.

EGFR-targeting cancer drugs can cause skin rashes and other side effects.

Deucravacitinib helped a man regrow hair significantly.

Abrocitinib may effectively treat stubborn alopecia universalis.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Topical calcitriol may reduce hair loss from chemotherapy at higher doses.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

MK-5108 is safe and shows potential against tumors, especially alone.